An observational study in Coagulopathy, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged Up to 8 Years. Per ClinicalTrials.gov, last updated 2025-05-13.
Sponsored by Stanford University · Observational
Congenital heart surgery on cardio-pulmonary bypass (CPB) is associated with impacted coagulation quality and increased bleeding after separation of CPB.
The current testing device used at our institution is the "TEG 5000" (Haemonetics Corporation). The novel coagulation testing device "Quantra System" (Hemosonics) has favorable properties (result within 20 minutes) allowing for a quicker identification of the coagulation problem and hence faster administration of the correct coagulation products, potentially leading to better coagulation quality and possibly reducing the need of additional blood products. The aim of this prospective observational (non-interventional, investigational only) quality improvement study is to investigate if the Quantra is reliable and valid in predicting the coagulation status when compared with our standard-of-care device TEG 5000.
Congenital heart surgery on cardio-pulmonary bypass (CPB) is associated with impacted coagulation quality and increased bleeding after separation of CPB. Therefore, coagulation products and blood products often need to be given/transfused during these cases. The correct choice and dosing of coagulation products is essential to effectively stop bleeding and reduce the need of additional blood transfusion.
The current testing device used at our institution during congenital heart surgery on CPB is the TEG 5000 (Haemonetics Corporation). Prior to separation from CPB (mostly 30-60 minutes) and after the first coagulation products were given (approx. 60 minutes after separation from CPB) a Clauss Fibrinogen and a TEG are drawn. These samples are sent to an off-site lab for processing and time to result ranges from 60-90 minutes. Therefore, results are often not present when needed.
An easy to use point-of-care (POC) test device being readily available in the operation room and allowing for rapid results could result in quicker identification of the coagulation problem and hence allow for faster administration of the correct coagulation products, potentially leading to better coagulation quality and possibly reducing the need of additional blood products.
The Quantra System (Hemosonics) is an easy-to-use, stand-alone device presenting results within 20 minutes. With these properties all above mentioned problems would be addressed. To date the Quantra has not been used and has not been evaluated in patients with congenital heart disease for cardiac surgery on CPB.
The aim of this prospective observational (non-interventional, investigational only) quality improvement study is to investigate if the Quantra is reliable and valid in predicting the coagulation status when compared with our standard-of-care device TEG
All patients who are enrolled in this study will be patients who are scheduled to undergo cardiac surgery and who require a general anesthesia, endotracheal intubation, arterial line placement and coagulation testing as part of standard of care for the surgery.
No patient will have a general anesthesia, endotracheal intubation, arterial line inserted or coagulation testing for research purposes only.
If the family/patient consent to be enrolled in the study the patient will be included in the study. It is standard of care to draw blood samples for coagulation testing (TEG and Clauss Fibrinogen) prior to separation of cardio-pulmonary-bypass (t1) and after the first coagulation products were given (t2), resulting in 2 x 5.4mL of blood.
For testing of efficacy/reliability/validity of the Quantra System we will need to draw additional blood samples (2.7mL) for each time point t1 and t2, resulting in a total of 2 x 2.7mL. These extra 5.4mL of blood drawn during the research portion of this study is additional to what they need for the surgical procedure and is not standard of care.
No clinical decision will be made on the results of the Quantra System. This is an investigational, non-interventional study.
503 studies on the registry are indexed under Hemostatic Disorders; 71 are open to participants now.
This study's enrollment of 40 is below the median of 100 across 229 observational studies indexed under Hemostatic Disorders.
Browse Hemostatic Disorders studies →Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.
Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
All patients with congenital heart disease scheduled for cardiac surgery on cardio-pulmonary bypass at our institution Age range is 0 to 8 years. There are no enrollment restrictions related to gender or ethnic background.
Exclusion Criteria:
The purpose of this study is to evaluate the efficacy/reliability/validity of the Quantra device in patients with congenital heart disease for cardiac surgery on CPB. The study if of investigational interest only. No clinical decisions will be made based on the results obtained by the Quantra device.
Correlation Quantra vs TEG_Fibrinogen_Function1
Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with TEG (K time \& alpha angle)
Time frame: 30 minutes during anesthesia, prior to separation from CPB
Correlation Quantra vs TEG_Fibrinogen_Function1
Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with TEG (K time \& alpha angle)
Time frame: 30 minutes during anesthesia, after coagulation products were given
Correlation Quantra vs TEG_Fibrinogen_Function2
Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with Clauss Fibrinogen.
Time frame: 30 minutes during anesthesia, prior to separation from CPB
Correlation Quantra vs TEG_Fibrinogen_Function2
Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with Clauss Fibrinogen.
Time frame: 30 minutes during anesthesia, after coagulation products were given
Correlation Quantra vs TEG_Platelet_Function
Correlation/Linear regression/normal_vs_abnormal of Quantra (CS/PCS) with TEG (MA)
Time frame: 30 minutes during anesthesia, prior to separation from CPB
Correlation Quantra vs TEG_Platelet_Function
Correlation/Linear regression/normal_vs_abnormal of Quantra (CS/PCS) with TEG (MA)
Time frame: 30 minutes during anesthesia, after coagulation products were given
Correlation Quantra vs TEG_clot initiation
Correlation/Linear regression/normal_vs_abnormal of Quantra (CT/CTH) with TEG (R time)
Time frame: 30 minutes during anesthesia, prior to separation from CPB
Correlation Quantra vs TEG_clot initiation
Correlation/Linear regression/normal_vs_abnormal of Quantra (CT/CTH) with TEG (R time)
Time frame: 30 minutes during anesthesia, after coagulation products were given
Correlation Quantra vs TEG_clot strength/firmness
Correlation/Linear regression/normal_vs_abnormal of Quantra (CS) with TEG (G value)
Time frame: 30 minutes during anesthesia, prior to separation from CPB
Correlation Quantra vs TEG_clot strength/firmness
Correlation/Linear regression/normal_vs_abnormal of Quantra (CS) with TEG (G value)
Time frame: 30 minutes during anesthesia, after coagulation products were given
Plan to share: No
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stanford University